Can-Fite BioPharma announced that positive Phase 2a study results of Namodenoson, a drug for advanced pancreatic ductal adenocarcinoma, have been accepted for presentation at the ESMO Congress 2026. The study showed durable disease stabilization and encouraging survival in patients who had progressed after standard therapies, with one second-line patient alive over 18 months. Namodenoson, targeting the A3 adenosine receptor, has a strong safety profile and is being further developed in combination with chemotherapy in a planned Phase 2b trial. This recognition at a leading oncology conference supports continued development of Namodenoson for this hard-to-treat cancer.
Truist Financial raised its price target for Global Payments from $79 to $95, reflecting optimism about the fintech company's prospects. Major institutional investors like Bank of New York Mellon and Pzena Investment Management have increased their s...
Scotiabank reported a strong quarterly performance with earnings per share of $1.64, surpassing analyst estimates of $1.53. The bank's net income rose 21% year-over-year to C$3 billion, driven by a 16% revenue increase to $7.52 billion. Growth was fu...
Napco Security Technologies reported record Q4 fiscal 2026 net sales of $55.8 million, a 10% increase driven by strong growth in recurring service revenue and equipment sales. The company's profitability improved significantly, with gross margins ris...
Nike is struggling with tough competition and economic pressures, causing sluggish sales and a 75% stock decline over five years. Despite this, analyst Jefferies rates Nike as a 'Buy,' citing its low valuation and a 4% forward dividend yield, which i...
Bank of Montreal reported quarterly earnings per share of $2.84, surpassing analyst expectations of $2.71, driven by a 19% rise in adjusted net income to $2.86 billion and revenue of $7.11 billion, exceeding forecasts. The bank's improved profitabili...
